Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 3/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CCR8 | P51685 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577668 | 0.92 | PDE4A (0.52) | KCNH2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5577917 | 0.87 | PDE4A (0.47) | CHRM3KCNH2PDE4APDE4BPDE4C | |
| SCHEMBL5577349 | 0.87 | CHRM3 (0.52) | CHRM3KCNH2ALDH1A1ACKR3 | |
| SCHEMBL5577375 | 0.86 | GAA (0.46) | CHRM3KCNH2SMN1; SMN2GAALMNA | |
| SCHEMBL5577287 | 0.85 | ACKR3 (0.48) | KCNH2SMN1; SMN2GAALMNACCR8 | |
| SCHEMBL5577794 | 0.83 | GAA (0.44) | KCNH2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5577728 | 0.81 | GAA (0.44) | KCNH2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5577323 | 0.81 | KCNH2 (0.46) | KCNH2PDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL5577653 | 0.81 | KDM4E (0.56) | SMN1; SMN2GAALMNAALDH1A1 | |
| SCHEMBL5916204 | 0.80 | OPRL1 (0.57) | PDE4APDE4BPDE4CPDE4DDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | CHRM3 2099/4885KCNH2 3617/4885PDE4A 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.